Immunobiotics are the Novel Biotech Drugs with Antibacterial and Immunomodulatory Properties

Лазаренко, Л. М.; Бабенко, Л. П.; Bubnov, Rostyslav; Demchenko, O.; Zotsenko, Volodymyr; Boyko, Nadiya; Spivak, Mykola; Diaprof, Lcl

doi:10.15407/microbiolj79.01.066

Cited by 12 publications

(12 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We speculate that immune-centered theory [66,67], claiming that gut microbiota can influence immune function beyond the gut, would be crucially helpful for choosing appropriate probiotic bacteria in the personalized clinical setting [42,68]. Therefore, the selected probiotics should improve lipid metabolism by reducing the level of total cholesterol and LDL cholesterol.…”

Section: Overviewmentioning

confidence: 99%

“…bulgaricus IMV B-7281, B. animalіs VKL and B. animalіs VKB (separately) and in various compositions had effective hypocholesterolemic activity in vitro [52]. These probiotic strains have a high level of ability to balance the immune response via induction of various cytokines and modifying gut microbiota (Lazarenko et al, 2017) [68], and were effective for monosodium glutamate-induced obesity [70]. Our recent data demonstrated strong correlations between bacteria wall elasticity with immune-modulatory properties that facilitate selection of the most effective probiotic drugs [71].…”

Section: Overviewmentioning

confidence: 99%

See 1 more Smart Citation

Comparative study of probiotic effects of Lactobacillus and Bifidobacteria strains on cholesterol levels, liver morphology and the gut microbiota in obese mice

et al. 2017

View full text Add to dashboard Cite

show abstract

Section: Overviewmentioning

confidence: 99%

Section: Overviewmentioning

confidence: 99%

Comparative study of probiotic effects of Lactobacillus and Bifidobacteria strains on cholesterol levels, liver morphology and the gut microbiota in obese mice

et al. 2017

View full text Add to dashboard Cite

show abstract

“…In addition, these strains of lactobacilli are characterized by specific immunomodulatory properties studied earlier in experiments on mice of the BALB / C line [3] and synergistic properties [6]. In similar studies, we have shown the ability of probiotic microorganisms to stimulate the local immune response and mechanisms that provide it [15,19].…”

Section: Methodsmentioning

confidence: 58%

“…Based on the results of our previous studies [3,15], we have proposed the principles of creating a new generation FFP based on plant components and microorganisms for the purpose of their prognostic and personified application for preventing the emergence of noncommunicable diseases [6], through correction of microbial cenosis in the intestines of the macroorganism .…”

Section: Resultsmentioning

confidence: 99%

Novel functional food for prevention of non-communicable diseases

Баті¹,

Boyko²,

Faculty³

2019

Biol. Stud.

View full text Add to dashboard Cite

Bati V. V., Boyko N. V. Novel functional food for prevention of non-communicable diseases. Studia Biolo gica, 2019: 13(1); 71-84 • DOI: https://doi.org/10. 30970/sbi.1301.589 V. V. Bati, N. V. Boyko ISSN 1996 • ISSN 2311-0783 (on-line) • Біологічні Студії / Studia Biologica • 2019 • Том 13/№1 • С. 71-84 methicillin-resistant S. aureus (MRSA), Enterobacter cloacae. The same effect was observed for the E. coli ATCC 25922 collection strain. The dairy drink with cherry plum showed antibacterial activity against strains of microorganisms: E. coli ATCC 25922, EPEC, S. aureus, MRSA, S. enteritidis, S. dysenteriae, Pseudomonas aeruginosa, Enterobacter cloacae. The dairy product with blueberries was suppressed by: P. aeruginosa, M. morganii, Listeria monocytogenes, S. enteritidis, S. dysenteriae, S. aureus, E. coli ATCC 25922, EPEC, MRSA, and also comensal strains of E. coli 058 and E. coli Schaedler's. However, it has been noted that a suppressive action was increased with the addition of native extracts (blueberries / cherry plum / dill / pomegranate). Cherry plum and pomegranate had a greater antagonistic effect on Klebsiella pneumonia and K. oxytoca. At the same time, a new generation FFP stimulated growth of representatives of useful microbiota.

show abstract

“…The gut microbiota is considered an extension of the self and, together with the genetic makeup, determines the physiology of an organism, metabolism and digestion. Intestinal microbial population largely represented by Bacteroidetes and Firmicutes, has been proven to impact on human health and maintaining homeostasis [4][5][6][7][8][9][10]. The gut microbiota has been recognized as an important contributor to pathological conditions such as obesity and metabolic disorders.…”

Section: Microbiota and Metabolic Syndrome: Strains Stratification Fomentioning

confidence: 99%

Towards Individualized Use of Probiotics and Prebiotics for Metabolic Syndrome and Associated Diseases Treatment: Does Pathophysiology-Based Approach Work and Can Anticipated Evidence Be Completed?

Bubnov¹,

Spivak²

2018

Preprint

View full text Add to dashboard Cite

The modification the gut microbiota in metabolic syndrome and associated chronic diseases is among leading tasks of microbiome research and needs for clinical use of probiotics. Evidence lack for the implications for microbiome modification to improve metabolic health in particular when applied impersonalized. Probiotics have tremendous potential in personalized nutrition and medicine to develop healthy diets. The aim was to to conduct comprehensive overview of recent updates of role of microbiota on human health and development of metabolic syndrome and efficacy of microbiota modulation considering specific properties of probiotic strain and particular aspects of metabolic syndrome and patient`s phenotype to fill the gap between probiotic product and individual to facilitate development of individualized / personalized probiotic and prebiotic treatments. We discuss the relevance of using host phenotype-associated biomarkers, those based on imaging and molecular and patrient`s history, reliable and accessible to facilitate person-specific appication of probiotics and prebiotic substances. Microbiome phenotypes can be parameters of predictive medicine to recognize patient`s predispositions and evaluate treatment responses; the number of phenotype markers can be effectively involved to monitor microbiome modulation. The studied strain-dependent properties of probiotic strains are potentially relevant for individualized treatment for gut and distant sites microbiome modulation. The evidence regarding probiotic strains properties can be taken to account via pathophysiology-based approach for most effective individualized treatment via gut, oral and vaginal and other sites microbiome modulation according to phenotype of the patient providing individualized and personalized medical approaches. Preventive potential of probiotics is strong and well-documented. Recommendations for individualized clinical use of probiotics, and for probiotic studies design have been suggested.

show abstract

Immunobiotics are the Novel Biotech Drugs with Antibacterial and Immunomodulatory Properties

Cited by 12 publications

References 17 publications

Comparative study of probiotic effects of Lactobacillus and Bifidobacteria strains on cholesterol levels, liver morphology and the gut microbiota in obese mice

Comparative study of probiotic effects of Lactobacillus and Bifidobacteria strains on cholesterol levels, liver morphology and the gut microbiota in obese mice

Novel functional food for prevention of non-communicable diseases

Towards Individualized Use of Probiotics and Prebiotics for Metabolic Syndrome and Associated Diseases Treatment: Does Pathophysiology-Based Approach Work and Can Anticipated Evidence Be Completed?

Contact Info

Product

Resources

About